{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50","upperLimit":"80","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction Cycles 1-3: Methotrexate 8gm/m\\^2 days 1 \\& 15; Leucovorin 100 mg/m\\^2 days 2 \\& 16; Rituximab 375 mg/m\\^2 days 3, 10, 17 \\& 24 of cycle 1, days 3 \\& 10 of cycle 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nInduction Cycle 4: Temozolomide 150 mg/m\\^2/day PO days 7-11; Methotrexate 8gm/m\\^2 day 15; Leucovorin 100 mg/m\\^2 day 16\n\nConsolidation Cycle 5: Methotrexate 8gm/m\\^2 days 1; Leucovorin 100 mg/m\\^2 days 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nConsolidation Cycle 6: Cytarabine 2 g/m\\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\\^2/day starting day 14 until ANC recovers (\\>= 500 for 2 consecutive days or \\>= 1500 for one day)","id":"OG000","title":"Intensive Combination Chemo & Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 months","title":"Complete Response Rate After Remission Induction","type":"PRIMARY","unitOfMeasure":"percentage of participants"}